The Long Journey of Cancer Biomarkers from the Bench to the Clinic

Abstract

BACKGROUND Protein cancer biomarkers serve multiple clinical purposes, both early and late, during disease progression. The search for new and better biomarkers has become an integral component of contemporary cancer research. However, the number of new biomarkers cleared by the US Food and Drug Administration has declined substantially over the last 10 years, raising concerns regarding the efficiency of the biomarker-development pipeline. CONTENT We describe different clinical uses of cancer biomarkers and their performance requirements. We also present examples of protein cancer biomarkers currently in clinical use and their limitations. The major barriers that candidate biomarkers need to overcome to reach the clinic are addressed. Finally, the long and arduous journey of a protein cancer biomarker from the bench to the clinic is outlined with an example. SUMMARY The journey of a protein biomarker from the bench to the clinic is long and challenging. Every step needs to be meticulously planned and executed to succeed. The history of clinically useful biomarkers suggests that at least a decade is required for the transition of a marker from the bench to the bedside. Therefore, it may be too early to expect that the new technological advances will catalyze the anticipated biomarker revolution any time soon.

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA

“…However, multiple preanalytical, analytical and post-analytical issues should be overcome and studies on the assay validations with regard to repeatability and reproducibility are also necessary [83]. The lack of effective biomarkers for early detection, prognosis of clinical outcome and response to treatment contributes to the maintenance of low survival rates for ovarian cancer patients, despite the numerous research studies on the field, the last decades.…”

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

“…However, despite numerous biomarker publications over the years (1), only a handful of new cancer biomarkers have successfully completed the journey from discovery, qualification, to verification and validation (2)(3)(4). One possible way to overcome this challenge is to develop an integrated biomarker pipeline that facilitates the smooth and successful transition from discovery to validation (5)(6)(7)(8)(9)(10).…”

Peptidomics of Urine and Other Biofluids for Cancer Diagnostics

“…Even fewer have been approved for population screening or diagnosis (3 ). One of the most frequently used cancer biomarkers is prostate-specific antigen (PSA).…”

“…For retrospective and prospective validation studies of candidate molecules and to avoid artifacts and methodology-related false-positive results, other methodologies (e.g., immunoassays) are preferred (3,77 ). Sometimes initial studies based on small populations show a statistical significance that, because of bias in patient selection or other confounders, becomes lost in subsequent studies.…”